Related Experiment Videos
ACE inhibitors and calcium antagonists in the treatment of congestive heart failure
1Department of Cardiology, Hvidovre University Hospital, Copenhagen, Denmark.
Insights
Angiotensin-converting enzyme (ACE) inhibitors reduce heart failure progression and cardiovascular events post-myocardial infarction. Verapamil shows promise in preventing reinfarction and sudden death, suggesting combination therapy potential.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Increased mortality post-myocardial infarction (MI) is linked to reinfarction, sudden death, and heart failure progression.
- Congestive heart failure mortality stems from disease progression and sudden death.
- ACE inhibitors are established in preventing cardiovascular events in post-MI patients with reduced ejection fraction and heart failure.
Purpose of the Study:
- To review the efficacy of ACE inhibitors and calcium antagonists in managing post-myocardial infarction and congestive heart failure.
- To explore potential benefits of combination therapy for cardiovascular outcomes.
Main Methods:
- Review of major clinical trials including SAVE, AIRE, and SOLVD for ACE inhibitor effects.
- Analysis of calcium antagonists (nifedipine, diltiazem, verapamil) in post-MI patient subgroups.
- Evaluation of treatment outcomes regarding mortality, morbidity, reinfarction, sudden death, and heart failure progression.
Main Results:
- ACE inhibitors significantly prevent heart failure progression and cardiovascular death in post-MI and congestive heart failure patients.
- Nifedipine showed no impact on mortality or morbidity post-MI.
- Diltiazem improved prognosis in specific patient groups (no CHF, non-Q-wave MI); verapamil reduced reinfarction and sudden death.
Conclusions:
- ACE inhibitors are crucial for managing heart failure post-MI.
- Verapamil demonstrates significant benefits in preventing reinfarction and sudden death.
- Combination therapy with verapamil and an ACE inhibitor warrants further investigation for enhanced cardiovascular protection.
Abstract:
The increased mortality after myocardial infarction is related to the risk of reinfarction, sudden death, and the development and progression of heart failure; in congestive heart failure it is due to the progression of heart failure and sudden death. ACE inhibitors have been proven to prevent cardiovascular events, especially the progression of heart failure, in postinfarct patients with reduced ejection fraction and heart failure in the SAVE and AIRE trials. In patients with congestive heart failure, ACE inhibitor treatment has prevented cardiovascular death and reduced morbidity due to progressive heart failure in the SOLVD trials. In post-myocardial infarction patients, the calcium antagonist nifedipine did not affect mortality or morbidity; diltiazem improved prognosis in patients without congestive heart failure and in patients with non-Q-wave infarction; and verapamil improved prognosis by prevention of reinfarction and sudden death. Combination treatment with both verapamil, which has pronounced antiischemic properties and prevents sudden death and reinfarction, and an ACE inhibitor, which prevents the progression of heart failure, is a possibility for future cardiovascular therapy that should be evaluated.